Online inquiry

IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3288MR)

This product GTTS-WQ3288MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets alpha toxin&
lukE gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000473596.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2828033; 59700577
UniProt ID P09616; A0A0H2WWN3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-alpha toxin&
lukE, ASN-1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3288MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8479MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ1129MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ11356MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ7815MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ118MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 11F8
GTTS-WQ15132MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ7859MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ4140MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW